{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T14:33:46Z","timestamp":1793370826971,"version":"4.5.0"},"reference-count":145,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T00:00:00Z","timestamp":1789084800000},"content-version":"vor","delay-in-days":10,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Medicine"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.clinme.2026.100643","type":"journal-article","created":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T14:29:27Z","timestamp":1789914567000},"page":"100643","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Updates to contemporary care of glioblastoma"],"prefix":"10.1016","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9745-9384","authenticated-orcid":false,"given":"Bernadeth Lyn C.","family":"Piamonte","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-1075-0932","authenticated-orcid":false,"given":"Wiley","family":"Gillam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7665-2692","authenticated-orcid":false,"given":"Megan E.H.","family":"Still","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5599-4610","authenticated-orcid":false,"given":"Ashley P.","family":"Ghiaseddin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matt","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Elsharkawy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6817-6657","authenticated-orcid":false,"given":"Christine","family":"Lu-Emerson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.clinme.2026.100643_bib1","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1001\/jama.2023.0023","article-title":"Glioblastoma and other primary brain malignancies in adults. A review","volume":"329","author":"Schaff","year":"2024","journal-title":"JAMA"},{"key":"10.1016\/j.clinme.2026.100643_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.canep.2025.102811","article-title":"Adult glioblastoma in England: incidence, treatment, and outcomes with novel population-based strata","volume":"97","author":"Le Calvez","year":"2025","journal-title":"Cancer Epidemiol"},{"issue":"10","key":"10.1016\/j.clinme.2026.100643_bib3","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1001\/jamaoncol.2022.2844","article-title":"World Health Organization 2021 classification of central nervous system tumors and implications for therapy for adult-type gliomas: a review","volume":"8","author":"Berger","year":"2022","journal-title":"JAMA Oncol"},{"issue":"1","key":"10.1016\/j.clinme.2026.100643_bib4","doi-asserted-by":"crossref","first-page":"146","DOI":"10.3390\/cancers17010146","article-title":"Glioblastoma: clinical presentation, multidisciplinary management, and long-term outcomes","volume":"17","author":"Sipos","year":"2025","journal-title":"Cancers"},{"issue":"10412","key":"10.1016\/j.clinme.2026.100643_bib5","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1016\/S0140-6736(23)01054-1","article-title":"Primary brain tumours in adults","volume":"402","author":"van den Bent","year":"2023","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.clinme.2026.100643_bib6","article-title":"Real-world analysis of treatment patterns and survival outcome of glioblastoma patients in a German single-center study: can survival rates of randomized controlled trials be achieved?","volume":"7","author":"Paus","year":"2025","journal-title":"Neuro-Oncol Adv"},{"issue":"5","key":"10.1016\/j.clinme.2026.100643_bib7","first-page":"381","article-title":"Brain and other central nervous system tumor statistics, 2021","volume":"71","author":"Miller","year":"2021","journal-title":"CA Cancer J Clin"},{"issue":"5","key":"10.1016\/j.clinme.2026.100643_bib8","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1056\/NEJMra0708126","article-title":"Malignant gliomas in adults","volume":"359","author":"Wen","year":"2008","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.clinme.2026.100643_bib9","first-page":"428","article-title":"A real-world claims analysis of costs and patterns of care in treated patients with glioblastoma multiforme in the United States","volume":"25","author":"Norden","year":"2019","journal-title":"J Manag Care Spec Pharm"},{"issue":"3","key":"10.1016\/j.clinme.2026.100643_bib10","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.21873\/anticanres.13251","article-title":"Healthcare costs for high-grade glioma","volume":"39","author":"Liu","year":"2019","journal-title":"Anticancer Res"},{"issue":"Suppl","key":"10.1016\/j.clinme.2026.100643_bib11","first-page":"Siv1","article-title":"CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2018-2022","volume":"27","author":"Price","year":"2025","journal-title":"Neuro Oncol"},{"issue":"11","key":"10.1016\/j.clinme.2026.100643_bib12","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1001\/jamaoncol.2016.1373","article-title":"Association of the extent of resection with survival in glioblastoma: a systematic review and meta-analysis","volume":"2","author":"Brown","year":"2016","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.clinme.2026.100643_bib13","doi-asserted-by":"crossref","first-page":"620","DOI":"10.3389\/fonc.2019.00620","article-title":"Survival outcomes among patients with high-grade glioma treated with 5-aminolevulinic acid-guided surgery: a systematic review and meta-analysis","volume":"9","author":"Gandhi","year":"2019","journal-title":"Front Oncol"},{"issue":"9","key":"10.1016\/j.clinme.2026.100643_bib14","doi-asserted-by":"crossref","first-page":"e404","DOI":"10.1016\/S1470-2045(24)00130-X","article-title":"The oncological role of resection in newly diagnosed diffuse adult-type glioma defined by the WHO 2021 classification: a review by the RANO resect group","volume":"25","author":"Karschnia","year":"2024","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.clinme.2026.100643_bib15","doi-asserted-by":"crossref","first-page":"987","DOI":"10.3171\/2023.7.JNS231170","article-title":"Use of 5-ALA fluorescence-guided surgery versus white-light conventional microsurgery for the resection of newly diagnosed glioblastomas (RESECT study): a French multicenter randomized phase III study","volume":"140","author":"Picart","year":"2023","journal-title":"J Neurosurg"},{"issue":"2","key":"10.1016\/j.clinme.2026.100643_bib16","doi-asserted-by":"crossref","first-page":"484","DOI":"10.3171\/2019.12.JNS191203","article-title":"Intraoperative MRI versus 5-ALA in high-grade glioma resection: a network meta-analysis","volume":"134","author":"Golub","year":"2020","journal-title":"J Neurosurg"},{"issue":"414","key":"10.1016\/j.clinme.2026.100643_bib17","article-title":"Biopsy vs. extensive resection for first recurrence of glioblastoma: is a prospective clinical trial warranted?","volume":"8","author":"Dardis","year":"2015","journal-title":"BMC Res Notes"},{"issue":"5","key":"10.1016\/j.clinme.2026.100643_bib18","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.3171\/2024.2.JNS232807","article-title":"Laser interstitial thermal therapy for first-line treatment of insular glioma","volume":"141","author":"Fadel","year":"2024","journal-title":"J Neurosurg"},{"issue":"1","key":"10.1016\/j.clinme.2026.100643_bib19","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1007\/s10143-024-03077-6","article-title":"Evaluating efficacy and safety of laser interstitial thermal therapy in patients with newly diagnosed and recurrent glioblastoma: a systematic review and meta-analysis","volume":"47","author":"Rangwala","year":"2024","journal-title":"Neurosurg Rev"},{"issue":"11","key":"10.1016\/j.clinme.2026.100643_bib20","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.3390\/cancers16112131","article-title":"Safety and efficacy of laser interstitial thermal therapy as upfront therapy in primary glioblastoma and IDH-mutant astrocytoma: a meta-analysis","volume":"16","author":"Pandey","year":"2024","journal-title":"Cancers"},{"issue":"5","key":"10.1016\/j.clinme.2026.100643_bib21","doi-asserted-by":"crossref","DOI":"10.3171\/2024.8.FOCUS24457","article-title":"Evaluating laser interstitial thermal therapy for newly diagnosed, deep-seated, large-volume glioblastoma: survival and outcome analysis","volume":"57","author":"Khalafallah","year":"2024","journal-title":"Neurosurg Focus"},{"issue":"2","key":"10.1016\/j.clinme.2026.100643_bib22","doi-asserted-by":"crossref","DOI":"10.3171\/2025.5.FOCUS25316","article-title":"Laser interstitial thermal therapy for high-grade glioma: a systematic review, meta-analysis, and meta-regression","volume":"59","author":"Mortezaei","year":"2025","journal-title":"Neurosurg Focus"},{"issue":"5","key":"10.1016\/j.clinme.2026.100643_bib23","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1227\/neu.0000000000002093","article-title":"Laser interstitial thermal therapy for first-line treatment of surgically accessible recurrent glioblastoma: outcomes compared with a surgical cohort","volume":"91","author":"Fadel","year":"2022","journal-title":"Neurosurgery"},{"issue":"4","key":"10.1016\/j.clinme.2026.100643_bib24","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1200\/JCO.21.02036","article-title":"Therapy for diffuse astrocytic and oligodendroglial tumors in adults: ASCO-SNO guideline","volume":"40","author":"Mohile","year":"2022","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.clinme.2026.100643_bib25","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1186\/s12957-016-0975-5","article-title":"Gliadel wafer implantation combined with standard radiotherapy and concurrent followed by adjuvant temozolomide for treatment of newly diagnosed high-grade glioma: a systematic literature review","volume":"14","author":"Ashby","year":"2016","journal-title":"World J Surg Oncol"},{"issue":"19","key":"10.1016\/j.clinme.2026.100643_bib26","doi-asserted-by":"crossref","first-page":"4920","DOI":"10.3390\/cancers14194920","article-title":"Applications of focused ultrasound for the treatment of glioblastoma: a new frontier","volume":"14","author":"Hersh","year":"2022","journal-title":"Cancers"},{"issue":"5","key":"10.1016\/j.clinme.2026.100643_bib27","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1111\/bpa.12171","article-title":"International Society of Neuropathology--Haarlem consensus guidelines for nervous system tumor classification and grading","volume":"24","author":"Louis","year":"2014","journal-title":"Brain Pathol"},{"issue":"8","key":"10.1016\/j.clinme.2026.100643_bib28","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","article-title":"The 2021 WHO classification of tumors of the central nervous system: a summary","volume":"23","author":"Louis","year":"2021","journal-title":"Neuro Oncol"},{"issue":"5","key":"10.1016\/j.clinme.2026.100643_bib29","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1007\/s00401-018-1913-0","article-title":"cIMPACT-NOW update 3: recommended diagnostic criteria for \u201cDiffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IV\u201d","volume":"136","author":"Brat","year":"2018","journal-title":"Acta Neuropathol"},{"issue":"4","key":"10.1016\/j.clinme.2026.100643_bib30","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1093\/neuonc\/noz200","article-title":"Survival of diffuse astrocytic glioma, IDH1\/2 wildtype, with molecular features of glioblastoma, WHO grade IV: a confirmation of the cIMPACT-NOW criteria","volume":"22","author":"Tesileanu","year":"2020","journal-title":"Neuro Oncol"},{"issue":"1","key":"10.1016\/j.clinme.2026.100643_bib31","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.ccr.2009.12.020","article-title":"Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1","volume":"17","author":"Verhaak","year":"2010","journal-title":"Cancer Cell"},{"issue":"7467","key":"10.1016\/j.clinme.2026.100643_bib32","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1038\/nature12627","article-title":"Tumour heterogeneity in the clinic","volume":"501","author":"Bedard","year":"2013","journal-title":"Nature"},{"issue":"6190","key":"10.1016\/j.clinme.2026.100643_bib33","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1126\/science.1254257","article-title":"Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma","volume":"344","author":"Patel","year":"2014","journal-title":"Science"},{"issue":"7697","key":"10.1016\/j.clinme.2026.100643_bib34","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1038\/nature26000","article-title":"DNA methylation-based classification of central nervous system tumours","volume":"555","author":"Capper","year":"2018","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.clinme.2026.100643_bib35","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s00401-020-02149-3","article-title":"Genome-wide DNA methylation profiles distinguish silent from non-silent ACTH adenomas","volume":"140","author":"Ricklefs","year":"2020","journal-title":"Acta Neuropathol"},{"issue":"8","key":"10.1016\/j.clinme.2026.100643_bib36","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1093\/neuonc\/noaa033","article-title":"Superiority of temozolomide over radiotherapy for elderly patients with RTK II methylation class, MGMT promoter methylated malignant astrocytoma","volume":"22","author":"Wick","year":"2020","journal-title":"Neuro Oncol"},{"issue":"22","key":"10.1016\/j.clinme.2026.100643_bib37","doi-asserted-by":"crossref","first-page":"8373","DOI":"10.1002\/cam4.3447","article-title":"Methylome analyses of three glioblastoma cohorts reveal chemotherapy sensitivity markers within DDR genes","volume":"9","author":"Kessler","year":"2020","journal-title":"Cancer Med"},{"issue":"1","key":"10.1016\/j.clinme.2026.100643_bib38","article-title":"Differences in methylation profiles between long-term survivors and short-term survivors of IDH-wildtype glioblastoma","volume":"6","author":"van der Meulen","year":"2024","journal-title":"Neuro-Oncol Adv"},{"issue":"6","key":"10.1016\/j.clinme.2026.100643_bib39","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1093\/neuonc\/noac004","article-title":"Liquid biopsy in gliomas: a RANO review and proposals for clinical applications","volume":"24","author":"Soffietti","year":"2022","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.clinme.2026.100643_bib40","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2025.1714287","article-title":"Cerebrospinal fluid ctDNA as a diagnostic and prognostic tool in gliomas: a systematic review and meta-analysis","volume":"15","author":"P\u00e9rez-Alfayate","year":"2025","journal-title":"Front Oncol"},{"issue":"1","key":"10.1016\/j.clinme.2026.100643_bib41","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1038\/s41698-026-01496-w","article-title":"Molecular features unique to circulating tumor DNA enable the tumor-na\u00efve liquid biopsy of glioblastoma","volume":"10","author":"Underhill","year":"2026","journal-title":"NPJ Precis Oncol"},{"issue":"10","key":"10.1016\/j.clinme.2026.100643_bib42","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1007\/s11604-025-01821-6","article-title":"RANO 2.0: critical updates and practical considerations for radiological assessment in neuro-oncology","volume":"43","author":"Sakata","year":"2025","journal-title":"Jpn J Radiol"},{"issue":"1","key":"10.1016\/j.clinme.2026.100643_bib43","doi-asserted-by":"crossref","DOI":"10.2217\/cns-2018-0007","article-title":"Use of the response assessment in neuro-oncology (RANO) criteria in clinical trials and clinical practice","volume":"8","author":"Chukwueke","year":"2019","journal-title":"CNS Oncol"},{"issue":"33","key":"10.1016\/j.clinme.2026.100643_bib44","doi-asserted-by":"crossref","first-page":"5187","DOI":"10.1200\/JCO.23.01059","article-title":"RANO 2.0: update to the response assessment in neuro-oncology criteria for high- and low-grade gliomas in adults","volume":"41","author":"Wen","year":"2023","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.clinme.2026.100643_bib45","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1093\/neuonc\/noad189","article-title":"RANO 2.0: the revised response assessment in neuro-oncology (RANO) criteria for high- and low-grade glial tumors in adults designed for the future","volume":"26","author":"Wen","year":"2024","journal-title":"Neuro Oncol"},{"issue":"5","key":"10.1016\/j.clinme.2026.100643_bib46","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s11910-013-0347-2","article-title":"Response assessment criteria for glioblastoma: practical adaptation and implementation in clinical trials of antiangiogenic therapy","volume":"13","author":"Chinot","year":"2013","journal-title":"Curr Neurol Neurosci Rep"},{"issue":"5","key":"10.1016\/j.clinme.2026.100643_bib47","doi-asserted-by":"crossref","first-page":"407","DOI":"10.3348\/kjr.2024.0016","article-title":"Summary of key points of the response assessment in neuro-oncology (RANO) 2.0","volume":"25","author":"Won","year":"2024","journal-title":"Korean J Radiol"},{"issue":"23","key":"10.1016\/j.clinme.2026.100643_bib48","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1056\/NEJM198012043032303","article-title":"Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery","volume":"303","author":"Walker","year":"1980","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.clinme.2026.100643_bib49","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1016\/0360-3016(79)90553-4","article-title":"An analysis of dose-effect relationship in the radiotherapy of malignant gliomas","volume":"5","author":"Walker","year":"1979","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"10.1016\/j.clinme.2026.100643_bib50","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1002\/1097-0142(19910701)68:1<22::AID-CNCR2820680105>3.0.CO;2-2","article-title":"A randomized study of chemotherapy with procarbazine, vincristine, and lomustine with and without radiation therapy for astrocytoma grades 3 and\/or 4","volume":"68","author":"Sandberg-Wollheim","year":"1991","journal-title":"Cancer"},{"issue":"15","key":"10.1016\/j.clinme.2026.100643_bib51","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1056\/NEJMoa065901","article-title":"Radiotherapy for glioblastoma in the elderly","volume":"356","author":"Keime-Guibert","year":"2007","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.clinme.2026.100643_bib52","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","volume":"352","author":"Stupp","year":"2005","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.clinme.2026.100643_bib53","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1038\/bjc.1991.396","article-title":"A Medical Research Council trial of two radiotherapy doses in the treatment of grades 3 and 4 astrocytoma. The Medical Research Council Brain Tumour Working Party","volume":"64","author":"Bleehen","year":"1991","journal-title":"Br J Cancer"},{"issue":"4","key":"10.1016\/j.clinme.2026.100643_bib54","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.prro.2016.03.007","article-title":"Radiation therapy for glioblastoma: executive summary of an American Society for Radiation Oncology evidence-based clinical practice guideline","volume":"6","author":"Cabrera","year":"2016","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.clinme.2026.100643_bib55","first-page":"279","article-title":"Combined modality approach to treatment of malignant gliomas - re-evaluation of RTOG 7401\/ECOG 1374 with long-term follow-up: a joint study of the radiation therapy oncology group and the eastern cooperative oncology group","volume":"6","author":"Nelson","year":"1988","journal-title":"NCI Monogr"},{"issue":"8","key":"10.1016\/j.clinme.2026.100643_bib56","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1093\/neuonc\/noab040","article-title":"A prospective phase II randomized trial of proton radiotherapy vs intensity-modulated radiotherapy for patients with newly diagnosed glioblastoma","volume":"23","author":"Brown","year":"2021","journal-title":"Neuro Oncol"},{"issue":"1","key":"10.1016\/j.clinme.2026.100643_bib57","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1186\/s13014-021-01962-8","article-title":"Glioblastoma radiotherapy using Intensity modulated Radiotherapy (IMRT) or proton Radiotherapy-GRIPS Trial (Glioblastoma Radiotherapy via IMRT or Proton BeamS): a study protocol for a multicenter, prospective, open-label, randomized, two-arm, phase III st","volume":"16","author":"K\u00f6nig","year":"2021","journal-title":"Radiat Oncol"},{"issue":"8","key":"10.1016\/j.clinme.2026.100643_bib58","article-title":"Comparative outcomes of standard radiation therapy and 5-fraction adaptive stereotactic radiation therapy in newly diagnosed glioblastoma: a propensity score-matched analysis","volume":"10","author":"Dohopolski","year":"2025","journal-title":"Adv Radiat Oncol"},{"issue":"2","key":"10.1016\/j.clinme.2026.100643_bib59","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/s11060-023-04523-z","article-title":"The role of GammaTile in the treatment of brain tumors: a technical and clinical overview","volume":"166","author":"Garcia","year":"2024","journal-title":"J Neurooncol"},{"issue":"30","key":"10.1016\/j.clinme.2026.100643_bib60","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.2217\/fon-2020-0558","article-title":"GammaTile\u00ae: surgically targeted radiation therapy for glioblastomas","volume":"16","author":"Gessler","year":"2020","journal-title":"Future Oncol"},{"issue":"7","key":"10.1016\/j.clinme.2026.100643_bib61","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1016\/S1470-2045(26)00235-4","article-title":"Dose escalation with intraoperative radiotherapy in newly diagnosed glioblastoma (INTRAGO-II): an open-label, multicentre, randomised, controlled, phase 3 trial","volume":"27","author":"Giordano","year":"2026","journal-title":"Lancet Oncol"},{"issue":"10","key":"10.1016\/j.clinme.2026.100643_bib62","doi-asserted-by":"crossref","first-page":"4129","DOI":"10.1007\/s00330-017-4789-9","article-title":"Diagnostic accuracy of magnetic resonance imaging techniques for treatment response evaluation in patients with high-grade glioma, a systematic review and meta-analysis","volume":"27","author":"van Dijken","year":"2017","journal-title":"Eur Radiol"},{"issue":"1","key":"10.1016\/j.clinme.2026.100643_bib63","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-16726-x","article-title":"Discriminators of pseudoprogression and true progression in high-grade gliomas: a systematic review and meta-analysis","volume":"12","author":"Taylor","year":"2022","journal-title":"Sci Rep"},{"issue":"13","key":"10.1016\/j.clinme.2026.100643_bib64","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1200\/JCO.2007.14.8163","article-title":"MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients","volume":"26","author":"Brandes","year":"2008","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.clinme.2026.100643_bib65","first-page":"52","article-title":"Patterns of bevacizumab use in patients with glioblastoma: an online survey among experts in neuro-oncology","volume":"7","author":"Ranjan","year":"2020","journal-title":"Neurooncol Pract"},{"issue":"10172","key":"10.1016\/j.clinme.2026.100643_bib66","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/S0140-6736(18)31791-4","article-title":"Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG\/NOA-09): a randomised, open-label, phase 3 trial","volume":"393","author":"Herrlinger","year":"2019","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.clinme.2026.100643_bib67","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1093\/annonc\/mdi225","article-title":"Temozolomide in combination with BCNU before and after radiotherapy in patients with inoperable newly diagnosed glioblastoma multiforme","volume":"16","author":"Barrie","year":"2005","journal-title":"Ann Oncol"},{"issue":"27","key":"10.1016\/j.clinme.2026.100643_bib68","doi-asserted-by":"crossref","first-page":"4412","DOI":"10.1200\/JCO.2006.06.9104","article-title":"Phase II trial of lomustine plus temozolomide chemotherapy in addition to radiotherapy in newly diagnosed glioblastoma: UKT-03","volume":"24","author":"Herrlinger","year":"2006","journal-title":"J Clin Oncol"},{"issue":"28","key":"10.1016\/j.clinme.2026.100643_bib69","doi-asserted-by":"crossref","first-page":"4733","DOI":"10.1200\/JCO.2008.19.8721","article-title":"Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma","volume":"27","author":"Friedman","year":"2009","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.clinme.2026.100643_bib70","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1200\/JCO.2008.16.3055","article-title":"Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma","volume":"27","author":"Kreisl","year":"2008","journal-title":"J Clin Oncol"},{"issue":"30","key":"10.1016\/j.clinme.2026.100643_bib71","doi-asserted-by":"crossref","first-page":"4722","DOI":"10.1200\/JCO.2007.12.2440","article-title":"Bevacizumab plus irinotecan in recurrent glioblastoma multiforme","volume":"25","author":"Vredenburgh","year":"2007","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.clinme.2026.100643_bib72","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJMoa1308345","article-title":"Bevacizumab plus radiotherapy\u2013temozolomide for newly diagnosed glioblastoma","volume":"370","author":"Chinot","year":"2014","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.clinme.2026.100643_bib73","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1308573","article-title":"A randomized trial of bevacizumab for newly diagnosed glioblastoma","volume":"370","author":"Gilbert","year":"2014","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.clinme.2026.100643_bib74","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/S1470-2045(23)00275-9","article-title":"Tumour-agnostic efficacy and safety of erdafitinib in patients with advanced solid tumours with prespecified FGFR alterations: RAGNAR phase 2 study primary analysis","volume":"24","author":"Pant","year":"2023","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.clinme.2026.100643_bib75","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1093\/neuonc\/noab274","article-title":"Efficacy and safety of larotrectinib in TRK fusion-positive primary central nervous system tumors","volume":"24","author":"Doz","year":"2022","journal-title":"Neuro Oncol"},{"issue":"7\u20138","key":"10.1016\/j.clinme.2026.100643_bib76","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1159\/000524399","article-title":"Larotrectinib response in NTRK3 fusion-driven diffuse high-grade glioma","volume":"107","author":"K\u00f6nig","year":"2022","journal-title":"Pharmacology"},{"issue":"Suppl 15","key":"10.1016\/j.clinme.2026.100643_bib77","article-title":"Activity of larotrectinib in TRK fusion cancer patients with brain metastases or primary central nervous system tumors","volume":"37","author":"Drilon","year":"2019","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.clinme.2026.100643_bib78","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1038\/s41416-018-0251-2","article-title":"Brief report: potent clinical and radiological response to larotrectinib in TRK fusion-driven high-grade glioma","volume":"119","author":"Ziegler","year":"2018","journal-title":"Br J Cancer"},{"issue":"10","key":"10.1016\/j.clinme.2026.100643_bib79","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1093\/neuonc\/noac087","article-title":"Entrectinib in children and young adults with solid or primary CNS tumors harboring NTRK, ROS1, or ALK aberrations (STARTRK-NG)","volume":"24","author":"Desai","year":"2022","journal-title":"Neuro Oncol"},{"issue":"1","key":"10.1016\/j.clinme.2026.100643_bib80","doi-asserted-by":"crossref","first-page":"4","DOI":"10.6004\/jnccn.2017.7032","article-title":"Rapid clinical and radiographic response with combined dabrafenib and trametinib in adults with BRAF-mutated high-grade glioma","volume":"16","author":"Johanns","year":"2018","journal-title":"J Natl Compr Cancer Netw"},{"issue":"4","key":"10.1016\/j.clinme.2026.100643_bib81","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.3390\/ijms19041090","article-title":"Dabrafenib treatment in a patient with an epithelioid glioblastoma and BRAF V600E mutation","volume":"19","author":"Ceccon","year":"2018","journal-title":"Int J Mol Sci"},{"issue":"35","key":"10.1016\/j.clinme.2026.100643_bib82","doi-asserted-by":"crossref","first-page":"3477","DOI":"10.1200\/JCO.2018.78.9990","article-title":"BRAF inhibition in BRAFV600-mutant gliomas: results from the VE-BASKET study","volume":"36","author":"Kaley","year":"2018","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.clinme.2026.100643_bib83","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S1470-2045(21)00578-7","article-title":"Dabrafenib plus trametinib in patients with BRAFV600E-mutant low-grade and high-grade glioma (ROAR): a multicentre, open-label, single-arm, phase 2, basket trial","volume":"23","author":"Wen","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clinme.2026.100643_bib84","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.17.00055","article-title":"Eleven month progression-free survival on vemurafenib monotherapy in a patient with recurrent and metastatic BRAF V600E-mutated glioblastoma WHO Grade 4","author":"Abadal","year":"2017","journal-title":"JCO Precis Oncol"},{"issue":"9","key":"10.1016\/j.clinme.2026.100643_bib85","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/S1470-2045(01)00489-2","article-title":"Current and future developments in the use of temozolomide for the treatment of brain tumours","volume":"2","author":"Stupp","year":"2001","journal-title":"Lancet Oncol"},{"issue":"19","key":"10.1016\/j.clinme.2026.100643_bib86","doi-asserted-by":"crossref","first-page":"10764","DOI":"10.1073\/pnas.96.19.10764","article-title":"Role of DNA mismatch repair and p53 in signaling induction of apoptosis by alkylating agents","volume":"96","author":"Hickman","year":"1999","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"10","key":"10.1016\/j.clinme.2026.100643_bib87","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1093\/neuonc\/noy016","article-title":"Temozolomide-associated hypermutation in gliomas","volume":"20","author":"Choi","year":"2018","journal-title":"Neuro Oncol"},{"issue":"10","key":"10.1016\/j.clinme.2026.100643_bib88","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1056\/NEJMoa043331","article-title":"MGMT gene silencing and benefit from temozolomide in glioblastoma","volume":"352","author":"Hegi","year":"2005","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.clinme.2026.100643_bib89","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1093\/neuonc\/noaa107","article-title":"A phase II randomized, multicenter, open-label trial of continuing adjuvant temozolomide beyond 6 cycles in patients with glioblastoma (GEINO 14-01)","volume":"22","author":"Balana","year":"2020","journal-title":"Neuro Oncol"},{"issue":"32","key":"10.1016\/j.clinme.2026.100643_bib90","doi-asserted-by":"crossref","first-page":"4085","DOI":"10.1200\/JCO.2013.49.6968","article-title":"Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial","volume":"31","author":"Gilbert","year":"2013","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.clinme.2026.100643_bib91","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/S1470-2045(12)70164-X","article-title":"Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial","volume":"13","author":"Wick","year":"2012","journal-title":"Lancet Oncol"},{"issue":"11","key":"10.1016\/j.clinme.2026.100643_bib92","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1093\/neuonc\/noab081","article-title":"Temozolomide-induced hypermutation is associated with distant recurrence and reduced survival after high-grade transformation of low-grade IDH-mutant gliomas","volume":"23","author":"Yu","year":"2021","journal-title":"Neuro Oncol"},{"issue":"5","key":"10.1016\/j.clinme.2026.100643_bib93","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1200\/JCO.2003.07.113","article-title":"Treatment-related myelodysplasia and acute leukemia in non-Hodgkin\u2019s lymphoma patients","volume":"21","author":"Armitage","year":"2003","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.clinme.2026.100643_bib94","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.bbcan.2017.01.004","article-title":"Chloroethylating nitrosoureas in cancer therapy: DNA damage, repair and cell death signaling","volume":"1868","author":"Nikolova","year":"2017","journal-title":"Biochem Biophys Acta Rev Cancer"},{"key":"10.1016\/j.clinme.2026.100643_bib95","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2020.102029","article-title":"How did lomustine become standard of care in recurrent glioblastoma?","volume":"87","author":"Weller","year":"2020","journal-title":"Cancer Treat Rev"},{"issue":"26","key":"10.1016\/j.clinme.2026.100643_bib96","doi-asserted-by":"crossref","first-page":"3212","DOI":"10.1200\/JCO.2012.47.2464","article-title":"Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma","volume":"31","author":"Batchelor","year":"2013","journal-title":"J Clin Oncol"},{"issue":"18","key":"10.1016\/j.clinme.2026.100643_bib97","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1200\/JCO-25-01137","article-title":"Evaluation of regorafenib in newly diagnosed and recurrent glioblastoma: GBM AGILE phase II\/III Bayesian randomized platform trial","volume":"44","author":"Wen","year":"2026","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.clinme.2026.100643_bib98","article-title":"Lung toxicity of lomustine in the treatment of progressive gliomas","volume":"4","author":"Seliger","year":"2022","journal-title":"Neurooncol Adv"},{"issue":"6","key":"10.1016\/j.clinme.2026.100643_bib99","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1038\/nm0603-669","article-title":"The biology of VEGF and its receptors","volume":"9","author":"Ferrara","year":"2003","journal-title":"Nat Med"},{"issue":"7","key":"10.1016\/j.clinme.2026.100643_bib100","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1200\/JCO.2009.23.2595","article-title":"Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma","volume":"28","author":"Wick","year":"2010","journal-title":"J Clin Oncol"},{"issue":"20","key":"10.1016\/j.clinme.2026.100643_bib101","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1056\/NEJMoa1707358","article-title":"Lomustine and bevacizumab in progressive glioblastoma","volume":"377","author":"Wick","year":"2017","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.clinme.2026.100643_bib102","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1200\/JCO.2014.55.9575","article-title":"Lessons from anti-vascular endothelial growth factor and anti-vascular endothelial growth factor receptor trials in patients with glioblastoma","volume":"33","author":"Lu-Emerson","year":"2015","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.clinme.2026.100643_bib103","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1016\/j.ijrobp.2009.12.061","article-title":"Randomized double-blind placebo-controlled trial of bevacizumab therapy for radiation necrosis of the central nervous system","volume":"79","author":"Levin","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"5","key":"10.1016\/j.clinme.2026.100643_bib104","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.2353\/ajpath.2007.070011","article-title":"Genetic pathways to primary and secondary glioblastoma","volume":"170","author":"Ohgaki","year":"2007","journal-title":"Am J Pathol"},{"issue":"6","key":"10.1016\/j.clinme.2026.100643_bib105","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/j.ccr.2011.11.005","article-title":"Mosaic amplification of multiple receptor tyrosine kinase genes in glioblastoma","volume":"20","author":"Snuderl","year":"2011","journal-title":"Cancer Cell"},{"issue":"6","key":"10.1016\/j.clinme.2026.100643_bib106","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1093\/neuonc\/nox191","article-title":"EGFR heterogeneity and implications for therapeutic intervention in glioblastoma","volume":"20","author":"Eskilsson","year":"2017","journal-title":"Neuro Oncol"},{"issue":"5","key":"10.1016\/j.clinme.2026.100643_bib107","first-page":"508","article-title":"Cetuximab, bevacizumab, and irinotecan for patients with primary glioblastoma and progression after radiation therapy and temozolomide: a phase II trial","volume":"12","author":"Hasselbalch","year":"2010","journal-title":"Neuro Oncol"},{"issue":"July 2","key":"10.1016\/j.clinme.2026.100643_bib108","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1093\/neuonc\/noac173","article-title":"Depatuxizumab mafodotin in EGFR-amplified newly diagnosed glioblastoma: a phase III randomized clinical trial","volume":"25","author":"Lassman","year":"2023","journal-title":"Neuro Oncol"},{"issue":"12","key":"10.1016\/j.clinme.2026.100643_bib109","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1093\/neuonc\/noab133","article-title":"Heterogeneous delivery across the blood-brain barrier limits the efficacy of an EGFR-targeting antibody drug conjugate in glioblastoma","volume":"23","author":"Marin","year":"2021","journal-title":"Neuro Oncol"},{"issue":"7","key":"10.1016\/j.clinme.2026.100643_bib110","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1093\/neuonc\/nov013","article-title":"Changes in the EGFR amplification and EGFRvIII expression between paired primary and recurrent glioblastomas","volume":"17","author":"van den Bent","year":"2015","journal-title":"Neuro Oncol"},{"issue":"7","key":"10.1016\/j.clinme.2026.100643_bib111","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1038\/ng.3590","article-title":"Clonal evolution of glioblastoma under therapy","volume":"48","author":"Wang","year":"2016","journal-title":"Nat Genet"},{"issue":"18","key":"10.1016\/j.clinme.2026.100643_bib112","article-title":"Tumor heterogeneity underlies clinical outcome and MEK inhibitor response in somatic NF1-mutant glioblastoma","volume":"10","author":"Pan","year":"2025","journal-title":"JCI Insight"},{"issue":"1","key":"10.1016\/j.clinme.2026.100643_bib113","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/S1470-2045(18)30675-2","article-title":"Regorafenib compared with lomustine in patients with relapsed glioblastoma (REGOMA): a multicentre, open-label, randomised, controlled, phase 2 trial","volume":"20","author":"Lombardi","year":"2019","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.clinme.2026.100643_bib114","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1038\/nrc2091","article-title":"The impact of translocations and gene fusions on cancer causation","volume":"7","author":"Mitelman","year":"2007","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"10.1016\/j.clinme.2026.100643_bib115","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.17.00055","article-title":"Eleven month progression-free survival on vemurafenib monotherapy in a patient with recurrent and metastatic BRAF V600E-mutated glioblastoma WHO Grade 4","author":"Beba Abadal","year":"2017","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.clinme.2026.100643_bib116","unstructured":"National Comprehensive Cancer Network. Central Nervous System Cancers [Internet]. NCCN Guidel Version 32026; 2026 [cited 2026 Aug 17]. Available from: NCCN.org."},{"issue":"8","key":"10.1016\/j.clinme.2026.100643_bib117","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1093\/neuonc\/noy027","article-title":"The clinical trials landscape for glioblastoma: is it adequate to develop new treatments?","volume":"20","author":"Vanderbeek","year":"2018","journal-title":"Neuro Oncol"},{"issue":"5","key":"10.1016\/j.clinme.2026.100643_bib118","first-page":"601","article-title":"Optimizing eligibility criteria and clinical trial conduct to enhance clinical trial participation for primary brain tumor patients","volume":"22","author":"Lee","year":"2020","journal-title":"Neuro Oncol"},{"issue":"Suppl 6","key":"10.1016\/j.clinme.2026.100643_bib119","doi-asserted-by":"crossref","first-page":"Svi71","DOI":"10.1093\/neuonc\/nox168.289","article-title":"EPID-11. Identifying barriers to clinical research: a pilot study to improve access and enrollment to neuro-oncology trials at Columbia University Center Medical Center (CUMC)","volume":"19","author":"Welch","year":"2017","journal-title":"Neuro Oncol"},{"issue":"2","key":"10.1016\/j.clinme.2026.100643_bib120","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1158\/1078-0432.CCR-17-1117","article-title":"Tumor-treating fields: a fourth modality in cancer treatment","volume":"24","author":"Mun","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"9","key":"10.1016\/j.clinme.2026.100643_bib121","doi-asserted-by":"crossref","first-page":"3288","DOI":"10.1158\/0008-5472.CAN-04-0083","article-title":"Disruption of cancer cell replication by alternating electric fields","volume":"64","author":"Kirson","year":"2004","journal-title":"Cancer Res"},{"issue":"8","key":"10.1016\/j.clinme.2026.100643_bib122","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1080\/09553002.2020.1837984","article-title":"An overview of potential novel mechanisms of action underlying tumor treating fields-induced cancer cell death and their clinical implications","volume":"97","author":"Karanam","year":"2021","journal-title":"Int J Radiat Biol"},{"key":"10.1016\/j.clinme.2026.100643_bib123","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.671972","article-title":"Efficacy and safety of tumor treating fields (TTFields) in elderly patients with newly diagnosed glioblastoma: subgroup analysis of the phase 3 EF-14 clinical trial","volume":"11","author":"Ram","year":"2021","journal-title":"Front Oncol"},{"issue":"Suppl","key":"10.1016\/j.clinme.2026.100643_bib124","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1053\/j.seminoncol.2014.03.011","article-title":"Characterization and management of dermatologic adverse events with the NovoTTF-100A system, a novel anti-mitotic electric field device for the treatment of recurrent glioblastoma","volume":"41","author":"Lacouture","year":"2014","journal-title":"Semin Oncol"},{"key":"10.1016\/j.clinme.2026.100643_bib125","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.3389\/fonc.2020.01045","article-title":"Prevention and management of dermatologic adverse events associated with tumor treating fields in patients with glioblastoma","volume":"10","author":"Lacouture","year":"2020","journal-title":"Front Oncol"},{"key":"10.1016\/j.clinme.2026.100643_bib126","series-title":"Alternating Electric Fields Therapy in Oncology: A Practical Guide to Clinical Applications of Tumor Treating Fields","first-page":"103","article-title":"Supportive care in patients using tumor treating fields therapy","author":"Wong","year":"2016"},{"key":"10.1016\/j.clinme.2026.100643_bib127","series-title":"Novocure Announces Topline Data from the Phase 3 TRIDENT Trial Evaluating Earlier Use of Tumor Treating Fields Therapy in Newly Diagnosed Glioblastoma [Internet]","author":"Novocure","year":"2026"},{"issue":"11","key":"10.1016\/j.clinme.2026.100643_bib128","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1093\/neuonc\/noac116","article-title":"Phase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated MGMT promoter","volume":"24","author":"Lim","year":"2022","journal-title":"Neuro Oncol"},{"issue":"1","key":"10.1016\/j.clinme.2026.100643_bib129","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1093\/neuonc\/noac099","article-title":"Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter: an international randomized phase III trial","volume":"25","author":"Omuro","year":"2023","journal-title":"Neuro Oncol"},{"issue":"3","key":"10.1016\/j.clinme.2026.100643_bib130","doi-asserted-by":"crossref","DOI":"10.1111\/cns.14563","article-title":"Theory and application of TTFields in newly diagnosed glioblastoma","volume":"30","author":"Yu","year":"2024","journal-title":"CNS Neurosci Ther"},{"issue":"Suppl 16","key":"10.1016\/j.clinme.2026.100643_bib131","article-title":"Final analysis of 2-THE-TOP: a phase 2 study of TTFields (Optune) plus pembrolizumab plus maintenance temozolomide (TMZ) in patients with newly diagnosed glioblastoma","volume":"41","author":"Tran","year":"2024","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.clinme.2026.100643_bib132","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1038\/s41591-024-02875-1","article-title":"Locoregional delivery of IL-13R\u03b12-targeting CAR-T cells in recurrent high-grade glioma: a phase 1 trial","volume":"30","author":"Brown","year":"2024","journal-title":"Nat Med"},{"issue":"8","key":"10.1016\/j.clinme.2026.100643_bib133","doi-asserted-by":"crossref","first-page":"2778","DOI":"10.1038\/s41591-025-03745-0","article-title":"Intracerebroventricular bivalent CAR T cells targeting EGFR and IL-13R\u03b12 in recurrent glioblastoma: a phase 1 trial","volume":"31","author":"Bagley","year":"2025","journal-title":"Nat Med"},{"key":"10.1016\/j.clinme.2026.100643_bib134","doi-asserted-by":"crossref","first-page":"3268","DOI":"10.1038\/s41591-026-04557-6","article-title":"Intracranial delivery of B7-H3-targeting CAR-T cells for recurrent glioblastoma: a phase 1 trial","volume":"32","author":"Zhang","year":"2026","journal-title":"Nat Med"},{"issue":"7738","key":"10.1016\/j.clinme.2026.100643_bib135","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1038\/s41586-018-0810-y","article-title":"Actively personalized vaccination trial for newly diagnosed glioblastoma","volume":"565","author":"Hilf","year":"2019","journal-title":"Nature"},{"issue":"7738","key":"10.1016\/j.clinme.2026.100643_bib136","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/s41586-018-0792-9","article-title":"Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial","volume":"565","author":"Keskin","year":"2019","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.clinme.2026.100643_bib137","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1001\/jamaoncol.2022.5370","article-title":"Association of autologous tumor lysate-loaded dendritic cell vaccination with extension of survival among patients with newly diagnosed and recurrent glioblastoma: a phase 3 prospective externally controlled cohort trial","volume":"9","author":"Liau","year":"2023","journal-title":"JAMA Oncol"},{"issue":"8","key":"10.1016\/j.clinme.2026.100643_bib138","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1056\/NEJMoa1000678","article-title":"Early palliative care for patients with metastatic non-small-cell lung cancer","volume":"363","author":"Temel","year":"2010","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.clinme.2026.100643_bib139","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1093\/neuonc\/noac216","article-title":"Palliative care and end-of-life care in adults with malignant brain tumors","volume":"25","author":"Koekkoek","year":"2023","journal-title":"Neuro Oncol"},{"issue":"9354","key":"10.1016\/j.clinme.2026.100643_bib140","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S0140-6736(03)12328-8","article-title":"Primary brain tumours in adults","volume":"361","author":"Behin","year":"2003","journal-title":"Lancet"},{"issue":"24","key":"10.1016\/j.clinme.2026.100643_bib141","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1212\/WNL.0b013e3181c67bce","article-title":"Medical decision-making capacity in patients with malignant glioma","volume":"73","author":"Triebel","year":"2009","journal-title":"Neurology"},{"key":"10.1016\/j.clinme.2026.100643_bib142","doi-asserted-by":"crossref","DOI":"10.1016\/j.clon.2026.104212","article-title":"Patterns and predictors of dying at home for adults with primary malignant brain tumours: a comprehensive national cohort analysis","volume":"57","author":"Calvez","year":"2026","journal-title":"Clin Oncol"},{"issue":"9","key":"10.1016\/j.clinme.2026.100643_bib143","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1016\/S1470-2045(12)70265-6","article-title":"Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial","volume":"13","author":"Malmstr\u00f6m","year":"2012","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.clinme.2026.100643_bib144","article-title":"Prognostic factors for overall survival in elderly patients with glioblastoma: analysis of the pooled NOA-08 and Nordic trials with the CCTG-EORTC (CE.6) trial","volume":"6","author":"Malmstr\u00f6m","year":"2024","journal-title":"Neurooncol Adv"},{"issue":"11","key":"10.1016\/j.clinme.2026.100643_bib145","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1056\/NEJMoa1611977","article-title":"Short-course radiation plus temozolomide in elderly patients with glioblastoma","volume":"376","author":"Perry","year":"2017","journal-title":"N Engl J Med"}],"container-title":["Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1470211826000928?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1470211826000928?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T13:56:29Z","timestamp":1793368589000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1470211826000928"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":145,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S1470211826000928"],"URL":"https:\/\/doi.org\/10.1016\/j.clinme.2026.100643","relation":{},"ISSN":["1470-2118"],"issn-type":[{"value":"1470-2118","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Updates to contemporary care of glioblastoma","name":"articletitle","label":"Article Title"},{"value":"Clinical Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinme.2026.100643","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd on behalf of Royal College of Physicians.","name":"copyright","label":"Copyright"}],"article-number":"100643"}}